MarketPulse
T

$TARA

2 articles found
2 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Protara Posts $57.4M Annual Loss as TARA-002 Bladder Cancer Data Bolsters Pipeline

Protara Therapeutics reported $57.4M full-year 2025 loss while unveiling promising 68% response rate for TARA-002 in bladder cancer trial with funding extending to 2028.
TARAfinancial resultsclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Protara Therapeutics to Present TARA-002 Data at Major Medical Conferences

Protara Therapeutics will present TARA-002 Phase 2 interim data at ASCO GU Symposium, showcasing results for BCG-unresponsive bladder cancer treatment.
TARAinvestor conferencebladder cancer